HL-003

HL-003 is a small molecule radioprotective agent developed by Shanghai Kechow Pharma. It is designed to protect normal tissues from the damaging effects of radiation and chemotherapy, with potential applications in radiation medicine and oncology. Mechanistically, HL-003 acts as a strong antioxidant and free radical scavenger, demonstrating higher activity than amifostine in preclinical studies. It protects DNA from radiation-induced damage by suppressing the expression of phosphorylated histone H2AX, phosphorylated p53, and apoptosis-related proteins such as caspase-8 and caspase-9. Preclinical data indicate that HL-003 has high efficacy, favorable safety profile, long half-life, oral bioavailability, and can cross the blood-brain barrier. The drug is currently in Phase 1 clinical trials for evaluation of its safety and pharmacokinetics in healthy subjects[1][2][3][4][5][7].